The Taliban’s New War Begins at Home 
Panama removed from EU’s tax haven ‘blacklist’ a decade after the Panama Papers 
Crackdown and Controversy: The Battle Over Beach Bars and Noise in Phuket’s Bang Tao 
By: Tomoaki Takei
Multinational pharma giant Eli Lilly’s Mounjaro (tirzepatide), the dual GIP/GLP-1 receptor agonist, is at the center of a rapidly escalating public health storm in East Asia. While clinically approved as a life-saving treatment for Type 2 diabetes, the drug has been effectively deified on social media as the ultimate cosmetic weight-los…
Don't Miss:
-
The Taliban’s New War Begins at Home
-
Panama removed from EU’s tax haven ‘blacklist’ a decade after the Panama Papers
-
Crackdown and Controversy: The Battle Over Beach Bars and Noise in Phuket’s Bang Tao
-
East Asia’s Youth Job Crisis Is Hiding Its Coming Labor Shortage
-
Leaked files reveal how Deloitte Cyprus helped Roman Abramovich hide $10B fortune